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As clinical trialists in osteoarthritis, we were repeatedly met
with the objection whether the difference between two
treatments (as measured by group difference in change of
disease status) was clinically relevant. To address this
unsettled problem, we report post hoc analyses of three
placebo-controlled clinical trials in knee osteoarthritis
where Lequesne’s 24-point pain and function index (ISK)
and a 100-mm visual analogue pain scale (VAS)1 to
measure global pain during the past week were used as
endpoints. The aim of this evaluation was to establish
change scores which are ‘minimal clinically relevant’2,3 as
distinguished from clinically unimportant. We postulate that
a difference between two treatments, one generating
relevant and the other unimportant change score is also of
clinical relevance.
Two groups were extracted from the three trials using all
patients with data available: patients who subjectively felt
their complaints were reduced after about half a year of
follow-up and those who expressed unaltered complaints at
that time point. Change score was calculated as absolute
change of ISK and VAS from baseline to half-year follow-up
in each patient. The difference in mean reduction of ISK
was 0.7. It was 8.4 mm regarding mean improvement on
VAS. Results were in accordance with cut off points deter-
mined by linear discriminant analysis: 0.4 (cut-off for
change of ISK) and 8.4 mm (cut off for change of VAS).
These data suggest which difference in change is
relevant to patients and may therefore be considered as a
difference which is relevant for treatments.Received 23 March 1998; accepted 24 March 1999.
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Fig. 1. ISK (upper panel) and VAS (lower panel) change score by
complaints. Bottom and top of boxes correspond to 25th and 75th
percentiles. The centre horizontal lines drawn at the median.
Whiskers extend to 10th and 90th percentiles.Methods, results and discussion
Three clinical trials in patients with knee osteoarthritis
(diagnosed according to the American College of Rheuma-
tology criteria) were performed in 1991/92 to evaluate an
intraarticular drug. Disease status was measured by
Lequesne’s 24 point pain and function index (ISK) and a
100-mm visual analogue scale (VAS)1 relating to globalpain during the past week. Measurements were performed
at baseline and, depending on study, after 22 or 26 weeks.
For each patient ISK and VAS change scores were deter-
mined as absolute difference from baseline to follow-up
score.
Twenty-two or 26 weeks after study start patients were
asked whether their complaints were increased, the same,
reduced, significantly reduced or completely gone (5-step
verbal rating scale). The mean ISK or VAS change score in
the group of patients with ‘reduced’ complaints was consid-
ered as clinically relevant for an individual patient. On the
other hand, a patient with the same amount of complaints
was deemed to have experienced unimportant change. Our
suggestion is to use the difference of clinically relevant and
unimportant change score as a guide to clinically relevant
difference between groups of patients or treatments.
All patients with data available—both verum and placebo
treated—were eligible for analysis (N=190). Figure 1
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respectively, by category of complaints.
Absolute improvement was 0.10±2.83 (mean±SD) for
ISK and 4.20±18.04 mm for VAS in patients with the same
amount of complaints. The patients with reduced com-
plaints, on the other hand, showed an improvement of
0.76±2.90 (ISK) and 12.56±24.27 mm (VAS). This resulted
in a difference of 0.7 in ISK and of 8.4 mm in VAS.
We also used linear discriminant analysis to determine
cut-off points to classify patients as having either ‘same
amount’ or ‘reduced’ complaints. Here, points are calcu-
lated which minimize the total probability of misclassifi-
cation, i.e., assigning a patient above cut-off to same
amount of complaints or below cut-off to reduced com-
plaints.4 Results were similar: 0.4 (change of ISK) and
8.4 mm (change of VAS). Applying the classification rule for
ISK score gives apparent error rates of 0.4 and 0.3 among
the 67 patients with reduced complaints and the 20 patients
with the same amount of complaints, respectively (or a 60%
specificity and a 70% sensitivity). For VAS score one has
error rates of 0.4 among both patients with reduced and
same amount of complaints (or both a 60% specificity and
sensitivity).
Both Fig. 1 and the error rates of classification pinpoint
the overlap of ISK and VAS change scores between
different categories of complaints. This may reflect in-
accurate answers of patients after a 6-month time period.
Thus, the question deserves attention whether to make the
patient’s opinion the gold standard by which to define a
clinically relevant treatment difference.
Recently, several scientific societies suggested clinical
outcome measures to be included in trials of osteo-
arthritis.5,6,7 A core set contains validated measures of pain
and physical function and patient global assessment.6,7 For
composite indices of pain and physical function, no defi-
nition of minimum clinically important change is currently
available.6 It does, however, exist for patient assessment:
any change of a patient’s disease status should be consid-
ered ‘minimal clinically relevant’, if the patient themself
thinks that they feel at least ‘a little better’.2,3 Thus, we
believe that the patient’s opinion—while being possibly
imprecise—is a valid measure of outcome which makes a
definition of clinically relevant response possible. In
essence, the definition reflects changes of ISK and VAS
which are relevant to a patient with knee osteoarthritis andthose which are not—and this may be particularly suited in
the absence of a structure-modifying drug.
The difference of change scores of a patient with same
amount and reduced complaints may be viewed as a
difference experienced by a typical patient on a treatment
generating relevant change and one on a treatment which
fails to do so (e.g., verum and placebo in a clinical trial).
Hence, we propose to view it as a relevant treatment
difference between groups of patients in a clinical trial.
However, further work is definitely needed to ultimately find
consensus on what constitute clinically relevant change for
an individual patient and clinically relevant difference
between treatments in this area.References
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